Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
185.00
-2.40 (-1.28%)
At close: Apr 28, 2026, 4:00 PM EDT
185.10
+0.10 (0.05%)
After-hours: Apr 28, 2026, 7:28 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 211.12, with a low estimate of 162 and a high estimate of 260. The average target predicts an increase of 14.12% from the current stock price of 185.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 7 | 7 | 7 |
| Buy | 11 | 11 | 11 | 10 | 9 | 9 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 21 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $251 → $259 | Strong Buy | Maintains | $251 → $259 | +40.00% | Apr 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $220 → $245 | Strong Buy | Maintains | $220 → $245 | +32.43% | Mar 25, 2026 |
| UBS | UBS | Strong Buy Maintains $248 → $251 | Strong Buy | Maintains | $248 → $251 | +35.68% | Feb 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $205 → $220 | Strong Buy | Maintains | $205 → $220 | +18.92% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $219 → $222 | Buy | Maintains | $219 → $222 | +20.00% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
1.00B
from 638.50M
Increased by 57.24%
Revenue Next Year
1.57B
from 1.00B
Increased by 55.88%
EPS This Year
-0.70
from -3.68
EPS Next Year
6.64
from -0.70
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.9B | ||||||
| Avg | 1.0B | 1.6B | ||||||
| Low | 890.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 67.9% | 92.4% | ||||||
| Avg | 57.2% | 55.9% | ||||||
| Low | 39.5% | 19.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.31 | 12.46 | ||||||
| Avg | -0.70 | 6.64 | ||||||
| Low | -2.14 | 1.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.